Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2022 Filed Aug 17, 2022 21:25 UTC |
Kelderman KimPRES. DIAGNOSTICS & GENOM
|
GrantRestricted Stock Units · Derivative | 1,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008784 · form4-08172022_020800.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · PRES. DIAGNOSTICS & GENOM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,746 Underlying: Common Stock · 1,746 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:23 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001437749-22-020846 · rdgdoc.xml · derivative · entry 10 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-08-15 F5 · derivative.exercise_date: 150,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 150,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:23 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 13,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-020846 · rdgdoc.xml · derivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,225 Underlying: Common Stock · 13,225 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: 4,408 shares vest on each of 8/15/2023 and 8/15/2025, and 4,409 shares vest on 8/15/2024. F4 · derivative.expiration_date: 4,408 shares vest on each of 8/15/2023 and 8/15/2025, and 4,409 shares vest on 8/15/2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:22 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-020845 · rdgdoc.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,984 Underlying: Common Stock · 1,984 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 661 shares vest on each of 8/15/2023 and 8/15/2025, and 662 shares vest on 8/15/2024. F3 · derivative.expiration_date: 661 shares vest on each of 8/15/2023 and 8/15/2025, and 662 shares vest on 8/15/2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:22 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 6,166 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001437749-22-020845 · rdgdoc.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock · 6,166 shares Expires 2029-08-15 F2 · derivative.exercise_date: Options to purchase 1,542 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 1,541 shares vest on 8/15/2024 and 8/15/2026. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 11,305 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 4 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,305 Underlying: Common Stock · 11,305 shares Expires 2029-08-15 F3 · derivative.exercise_date: Options to purchase 2,826 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026 and options to purchase 2,827 shares vest on 8/15/2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 8,479 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,479 Underlying: Common Stock · 8,479 shares Expires 2029-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 2,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,728 Underlying: Common Stock · 2,728 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 8 | $380.71 | $3,045.68 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,502 Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 504 | $385.47 | $194,276.58 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,510 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 385.2900 to 385.8900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,400 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · derivative · entry 7 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,400 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 992 | $380.15 | $377,111.78 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,014 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 380.0000 to 380.4400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 100 | $374.90 | $37,489.50 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,006 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 374.8950 to 374.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 900 | $373.99 | $336,592.62 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,106 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 373.8600 to 374.3300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 20:02 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 3,400 | $66.90 | $227,460.00 |
DisclosureSEC source: 0001437749-22-020338 · rdgdoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:08 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 563 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001437749-22-019862 · rdgdoc.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,562 Underlying: Common Stock · 563 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:08 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 563 | $177.32 | $99,831.16 |
DisclosureSEC source: 0001437749-22-019862 · rdgdoc.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 16,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · derivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/7/2022, the Board of Directors certified vesting of 16,937 performance RSUs. F4 · derivative.expiration_date: On 8/7/2022, the Board of Directors certified vesting of 16,937 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 11,557 | $382.97 | $4,425,984.29 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,403 F1 · balance_after: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:58 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019663 · rdgdoc.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 2,862 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 3,562 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionRestricted Stock Units · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · derivative · entry 6 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/7/2022, the Board of Directors certified vesting of 2,363 performance RSUs. F3 · derivative.expiration_date: On 8/7/2022, the Board of Directors certified vesting of 2,363 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Tax withholdingCommon Stock | 1,214 | $382.97 | $464,925.58 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,138 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 23:00 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019667 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · derivative · entry 11 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/7/22, the Board of Directors certified vesting of 1,969 performance RSUs. F3 · derivative.expiration_date: On 8/7/22, the Board of Directors certified vesting of 1,969 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 969 | $382.97 | $371,097.93 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · derivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/7/22, the Board of Directors certified vesting of 3,938 performance RSUs. F3 · derivative.expiration_date: On 8/7/22, the Board of Directors certified vesting of 3,938 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 1,938 | $382.97 | $742,195.86 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,755 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 45,346 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,346 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Tax withholdingCommon Stock | 27,707 | $380.76 | $10,549,717.32 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,042 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 22:11 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionCommon Stock | 45,346 | $108.49 | $4,919,587.54 |
DisclosureSEC source: 0001415889-22-008078 · form4-08012022_030829.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,346 Underlying: Common Stock · 50,000 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Tax withholdingCommon Stock | 30,935 | $362.78 | $11,222,599.30 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,403 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:18 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionCommon Stock | 50,000 | $108.49 | $5,424,500.00 |
DisclosureSEC source: 0001415889-22-007599 · form4-07082022_020741.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 600 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 4,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 600 | $366.09 | $219,654.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 366.0000 to 366.1900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 600 | $66.90 | $40,140.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 1,000 | $364.31 | $364,310.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 364.0000 to 364.6400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 1,000 | $66.90 | $66,900.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,104 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,346 Underlying: Common Stock · 5,104 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 5,104 | $365.00 | $1,862,960.00 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,338 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:05 UTC |
Kummeth Charles R.Director · CHIEF EXECUTIVE OFFICER
|
Exercise / conversionCommon Stock | 5,104 | $108.49 | $553,732.96 |
DisclosureSEC source: 0001415889-22-006391 · form4-06092022_020617.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| May 10, 2022 Filed May 11, 2022 20:52 UTC |
BAUMGARTNER ROBERT VDirector
|
PurchaseCommon Stock | 300 | $352.55 | $105,765.00 |
DisclosureSEC source: 0001415889-22-004847 · form4-05112022_010505.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:31 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,989 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-22-003021 · rdgdoc.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 1,989 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options to purchase 2,500 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 21:31 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 1,989 | $150.78 | $299,901.42 |
DisclosureSEC source: 0001437749-22-003021 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC |
Geist WilliamPresident, Protein Sciences
|
GrantStock Option (right to buy) · Derivative | 3,978 | $0.00 Strike: $401.57 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 4 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,978 Underlying: Common Stock · 3,978 shares Expires 2029-02-01 F4 · derivative.exercise_date: Options to purchase 995 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 994 shares vest on each of 2/1/2025 and 2/1/2026. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC |
Geist WilliamPresident, Protein Sciences
|
GrantStock Option (right to buy) · Derivative | 2,984 | $0.00 Strike: $401.57 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 3 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Common Stock · 2,984 shares Expires 2029-02-01 F3 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC |
Geist WilliamPresident, Protein Sciences
|
GrantRestricted Stock Units · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 2 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.